Over the last few weeks I have been fortunate enough to attend a range of meetings with the subject matter ranging from flexible facilities, through to gene therapy and the production of bacteriophage. Through these I start seeing common themes. The first of which is the challenges of producing small volume products down to patient specific medicines and the second that of affordability of new products and patient access to new medicines.
[inlinead]
This is becoming an increasing area of c...
